Literature DB >> 17343566

Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain.

Jean-Marc Taymans1, Luk H Vandenberghe, Chris Van Den Haute, Irina Thiry, Christophe M Deroose, Luc Mortelmans, James M Wilson, Zeger Debyser, Veerle Baekelandt.   

Abstract

Recombinant adeno-associated virus serotype 2 (rAAV2) vectors have been shown to deliver genes effectively to neurons in the brain, retina, and spinal cord. The characterization of new AAV serotypes revealed different patterns of transduction in a diverse array of tissues (Gao, G., Vandenberghe, L.H., and Wilson, J.M. [2005]. Curr. Gene Ther. 5, 285-297). Here, we extensively compare the neural tropism of human-derived rAAVs (types 2/1, 2, and 2/5) with nonhuman primate-derived rAAVs (types 2/7 and 2/8) in adult mouse brain. Mice were injected with rAAV type 2/1, 2, 2/5, 2/7, or 2/8 via the caudate-putamen and substantia nigra. Intrahippocampal injections were also performed for rAAV2/7 and rAAV2/8. In all regions injected, the vectors transduced neurons almost exclusively. Retrograde transduction of all rAAV pseudotypes was also observed in particular CNS areas. At high titers, all rAAV pseudotypes transduced comparable brain volumes in all targeted regions except for rAAV2, which transduced much smaller brain volumes. A dose-range comparison of intrastriatally injected rAAV types 2/5, 2/7, and 2/8 highlighted that the transduction efficiency, as determined by transduced volume and biophotonic imaging of green fluorescent protein expression intensity, was significantly higher for rAAV2/5 and rAAV2/7 compared with rAAV2/8 at low titers, whereas all three serotypes performed equally well at higher doses. These results demonstrate the use and efficiency of both human- and nonhuman primate-derived rAAV vectors for disease modeling and their potential for gene therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17343566     DOI: 10.1089/hum.2006.178

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  160 in total

1.  Suppression of endogenous PPARγ increases vulnerability to methamphetamine-induced injury in mouse nigrostriatal dopaminergic pathway.

Authors:  Seong-Jin Yu; Mikko Airavaara; Hui Shen; Jenny Chou; Brandon K Harvey; Yun Wang
Journal:  Psychopharmacology (Berl)       Date:  2011-12-13       Impact factor: 4.530

2.  Cortical representations of olfactory input by trans-synaptic tracing.

Authors:  Kazunari Miyamichi; Fernando Amat; Farshid Moussavi; Chen Wang; Ian Wickersham; Nicholas R Wall; Hiroki Taniguchi; Bosiljka Tasic; Z Josh Huang; Zhigang He; Edward M Callaway; Mark A Horowitz; Liqun Luo
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

Review 3.  Dissecting local circuits in vivo: integrated optogenetic and electrophysiology approaches for exploring inhibitory regulation of cortical activity.

Authors:  Jessica A Cardin
Journal:  J Physiol Paris       Date:  2011-09-19

4.  Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice.

Authors:  Françoise Piguet; Dolan Sondhi; Monique Piraud; Françoise Fouquet; Neil R Hackett; Ornella Ahouansou; Marie-Thérèse Vanier; Ivan Bieche; Patrick Aubourg; Ronald G Crystal; Nathalie Cartier; Caroline Sevin
Journal:  Hum Gene Ther       Date:  2012-07-23       Impact factor: 5.695

5.  Use of Adeno-Associated and Herpes Simplex Viral Vectors for In Vivo Neuronal Expression in Mice.

Authors:  Rachel D Penrod; Audrey M Wells; William A Carlezon; Christopher W Cowan
Journal:  Curr Protoc Neurosci       Date:  2015-10-01

6.  Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex.

Authors:  Annelies Gerits; Pascaline Vancraeyenest; Samme Vreysen; Marie-Eve Laramée; Annelies Michiels; Rik Gijsbers; Chris Van den Haute; Lieve Moons; Zeger Debyser; Veerle Baekelandt; Lutgarde Arckens; Wim Vanduffel
Journal:  Neurophotonics       Date:  2015-10-01       Impact factor: 3.593

7.  Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy.

Authors:  Umut Cagin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  cJun promotes CNS axon growth.

Authors:  Jessica K Lerch; Yania R Martínez-Ondaro; John L Bixby; Vance P Lemmon
Journal:  Mol Cell Neurosci       Date:  2014-02-09       Impact factor: 4.314

9.  Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain.

Authors:  Eleni A Markakis; Kenneth P Vives; Jeremy Bober; Stefan Leichtle; Csaba Leranth; Jeff Beecham; John D Elsworth; Robert H Roth; R Jude Samulski; D Eugene Redmond
Journal:  Mol Ther       Date:  2009-12-15       Impact factor: 11.454

10.  Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals.

Authors:  A Asokan; J S Johnson; C Li; R J Samulski
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.